GoAI
Get started
Longeveron Inc. logo

Longeveron Inc.

LGVN

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$0.8449

+$0.0167 · +2.02%

Aug 21, 4:00 PM ET

LGVN company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

32

Expensive

Momentum

28

Weakening

Sentiment

50

Mixed

Risk resilience

34

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Longeveron Inc. is a biotechnology company currently in the clinical development stage, dedicated to pioneering cell-based therapies. These treatments are designed to address both age-related conditions and various critical, life-threatening illnesses. The company's primary investigational product is LOMECEL-B, a sophisticated cellular therapy. This product is created from medicinal signaling cells that are cultivated and expanded after being harvested from the bone marrow of healthy young adult donors. Longeveron is actively conducting Phase 1 and Phase 2 clinical trials to evaluate LOMECEL-B's potential across a diverse range of indications. These include age-related frailty, Alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). Established in 2014, Longeveron Inc. operates from its headquarters in Miami, Florida.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Stephen H. Willard
Listed since
Feb 12, 2021
Employees
38

Market position

Day range

Current $0.8449

52-week range

Current $0.8449

Open
$0.86
Previous close
$0.8282
Volume
770.45K
1.95× average
Average volume
395.32K
Average daily volume
Market cap
16.84M USD
Beta
-0.25
Market reference 1
50-day average
$0.7091
+19.15% above average
200-day average
$0.7219
+17.04% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
5.06M USD
P/E (TTM)
-0.84×
P/B (TTM)
2.55×
P/S (TTM)
14.19×
EV / EBITDA
-0.24×
Earnings yield
-255.28%
Free cash flow yield
-212.40%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
69.76%
Operating margin
-1992.84%
Net margin
-1977.59%
Return on equity
-400.07%
Return on assets
-221.26%
Return on invested capital
-341.00%

Financial health

Debt / equity
0.06×
Current ratio
1.33×
Altman Z-score
-15.37
Piotroski F-score
2 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends389%-851%-2090%-3330%Gross margin, FY2021: 45.18%Gross margin, FY2022: 40.67%Gross margin, FY2023: 31.17%Gross margin, FY2024: 78.76%Gross margin, FY2025: 66.97%Operating margin, FY2021: -1336.60%Operating margin, FY2022: -1476.51%Operating margin, FY2023: -2966.01%Operating margin, FY2024: -690.72%Operating margin, FY2025: -1942.20%Net margin, FY2021: -1305.13%Net margin, FY2022: -1541.33%Net margin, FY2023: -3020.17%Net margin, FY2024: -667.77%Net margin, FY2025: -1893.58%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 45.18%. Gross margin FY2022 40.67%. Gross margin FY2023 31.17%. Gross margin FY2024 78.76%. Gross margin FY2025 66.97%. Operating margin FY2021 -1336.60%. Operating margin FY2022 -1476.51%. Operating margin FY2023 -2966.01%. Operating margin FY2024 -690.72%. Operating margin FY2025 -1942.20%. Net margin FY2021 -1305.13%. Net margin FY2022 -1541.33%. Net margin FY2023 -3020.17%. Net margin FY2024 -667.77%. Net margin FY2025 -1893.58%.

Income trends

Revenue

1.2M USD-49.87%

Operating income

−23.29M USD-40.95%

Net income

−22.7M USD-42.14%
Income trends across reported periods4.96M USD−5.31M USD−15.58M USD−25.85M USDRevenue, FY2021: 1.31M USDRevenue, FY2022: 1.22M USDRevenue, FY2023: 709K USDRevenue, FY2024: 2.39M USDRevenue, FY2025: 1.2M USDOperating income, FY2021: −17.46M USDOperating income, FY2022: −18.04M USDOperating income, FY2023: −21.03M USDOperating income, FY2024: −16.52M USDOperating income, FY2025: −23.29M USDNet income, FY2021: −17.05M USDNet income, FY2022: −18.84M USDNet income, FY2023: −21.41M USDNet income, FY2024: −15.97M USDNet income, FY2025: −22.7M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 1.31M USD. Revenue FY2022 1.22M USD. Revenue FY2023 709K USD. Revenue FY2024 2.39M USD. Revenue FY2025 1.2M USD. Operating income FY2021 −17.46M USD. Operating income FY2022 −18.04M USD. Operating income FY2023 −21.03M USD. Operating income FY2024 −16.52M USD. Operating income FY2025 −23.29M USD. Net income FY2021 −17.05M USD. Net income FY2022 −18.84M USD. Net income FY2023 −21.41M USD. Net income FY2024 −15.97M USD. Net income FY2025 −22.7M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue1.2M USD2.39M USD709K USD1.22M USD1.31M USD
Cost of goods sold396K USD508K USD488K USD725K USD716K USD
Gross profit803K USD1.88M USD221K USD497K USD590K USD
Research and development12.04M USD8.14M USD9.07M USD9.37M USD7.09M USD
Selling, general, and administrative12.05M USD10.27M USD12.18M USD9.17M USD10.95M USD
Operating expenses24.09M USD18.41M USD21.25M USD18.54M USD18.05M USD
Interest expense————4K USD
Depreciation and amortization1.23M USD958K USD946K USD893K USD914K USD
Operating income−23.29M USD−16.52M USD−21.03M USD−18.04M USD−17.46M USD
Net income−22.7M USD−15.97M USD−21.41M USD−18.84M USD−17.05M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
36%
4 beats, 5 misses, 2 met estimates
Average EPS surprise
-6.07%
11 comparable reports
Latest EPS result
-0.19
Estimate -0.18 · Miss by 8.57%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.13-0.24-0.36-0.47Q1 '25MissQ2 '25MetQ3 '25BeatQ4 '25MissQ1 '26BeatQ2 '26MetQ3 '26MissQ4 '26Estimate
Q1 2025, reported Feb 28, 2025: actual -0.434, estimate -0.36, surprise -20.51%, Miss. Q2 2025, reported May 8, 2025: actual -0.34, estimate -0.34, surprise 0.00%, Met estimate. Q3 2025, reported Aug 13, 2025: actual -0.33, estimate -0.35, surprise +5.71%, Beat. Q4 2025, reported Nov 4, 2025: actual -0.39, estimate -0.26, surprise -50.00%, Miss. Q1 2026, reported Mar 17, 2026: actual -0.22, estimate -0.42, surprise +47.62%, Beat. Q2 2026, reported May 13, 2026: actual -0.19, estimate -0.19, surprise 0.00%, Met estimate. Q3 2026, reported Aug 12, 2026: actual -0.19, estimate -0.175, surprise -8.57%, Miss. Q4 2026, reported Nov 3, 2026: actual —, estimate -0.15, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates675.88K481.85K287.82K93.78KQ1 '25MissQ2 '25MissQ3 '25MissQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26MissQ4 '26Estimate
Q1 2025, reported Feb 28, 2025: actual 603K USD, estimate 633.99K USD, surprise -4.89%, Miss. Q2 2025, reported May 8, 2025: actual 381K USD, estimate 592.67K USD, surprise -35.71%, Miss. Q3 2025, reported Aug 13, 2025: actual 316K USD, estimate 444K USD, surprise -28.83%, Miss. Q4 2025, reported Nov 4, 2025: actual 137K USD, estimate 110.33K USD, surprise +24.17%, Beat. Q1 2026, reported Mar 17, 2026: actual 365K USD, estimate 110.33K USD, surprise +230.82%, Beat. Q2 2026, reported May 13, 2026: actual 398K USD, estimate 334.5K USD, surprise +18.98%, Beat. Q3 2026, reported Aug 12, 2026: actual 287K USD, estimate 326K USD, surprise -11.96%, Miss. Q4 2026, reported Nov 3, 2026: actual —, estimate 400K USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$10.00

1083.57% upside
Past 12 months12-month forecast

Price history unavailable

High $10.00Average $10.00Low $10.00

Rating distribution

4 ratings

Limited analyst sample: 4 ratings. Interpret the distribution with caution.

Strong buy00%
Buy375%
Hold125%
Sell00%
Strong sell00%

Recent analyst actions

3 institutions
Roth CapitalmaintainBuy

LGVN news

globenewswire.com

Longeveron Appoints Nirav Jhaveri as Chief Financial Officer

Mr. Jhaveri has over 25 years of experience in capital markets, corporate finance, business development and investor relations, including more than 15 years in the biotech sector MIAMI, Aug. 19, 2026 (GLOBE NEWSWIRE) --…

Read source
seekingalpha.com

Longeveron Inc. (LGVN) Q2 2026 Earnings Call Transcript

Longeveron Inc. (LGVN) Q2 2026 Earnings Call Transcript

Read source
globenewswire.com

Longeveron Announces 2026 Second Quarter Financial Results and Provides Business Update

On track for September 2026 top-line results from Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for hypoplastic left heart syndrome (HLHS), a rare pediatric disease and…

Read source
globenewswire.com

Longeveron Named a Finalist Team and Will Receive a $1,000,000 Milestone 2 Award for the XPRIZE Healthspan Global Competition

Longeveron selected as a Milestone 2 Awardee based on published clinical trial results which demonstrated laromestrocel increased 6-minute walk distance in patients with Aging-related Frailty MIAMI, Aug. 11, 2026 (GLOBE…

Read source
globenewswire.com

Longeveron to Report 2026 Second Quarter Financial Results and Host Conference Call on August 12, 2026

MIAMI, Fla., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related…

Read source
globenewswire.com

Deborah D. Ascheim, M.D. Elected to Longeveron Board of Directors

MIAMI, July 23, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today…

Read source

Corporate actions

Corporate action history

Stock split

Effective Mar 27, 2024

1:10

LGVN peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding LGVN

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
253.45K
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
154.33K
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%

Continue in GoAI

Research LGVN

research.disclaimer